

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信基沙溪集团股份有限公司
XINJI SHAXI GROUP CO., LTD

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3603)

**CHANGE OF DIRECTORS
AND
CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The Board hereby announces the following changes with effect from 8 October 2026:

- (i) Mr. Zhao Hui has resigned as a non-executive Director;
- (ii) Dr. Zeng Zhaowu has been re-designated from an independent non-executive Director to a non-executive Director, and has ceased to act as the chairman of each of the Audit Committee and Remuneration Committee and a member of the Nomination Committee;
- (iii) Mr. Yu Ting has been appointed as an independent non-executive Director, the chairman of each of the Audit Committee and Remuneration Committee and a member of the Nomination Committee.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of Xinji Shaxi Group Co., Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. Zhao Hui (“**Mr. Zhao**”) has tendered his resignation as a non-executive Director with effect from 8 October 2026 as he would like to devote more time to his other engagements.

Mr. Zhao has confirmed that he has no disagreement with the Board and there is no matter in respect of his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Zhao for his valuable contributions to the Company during his tenure of office.

RE-DESIGNATION OF DIRECTOR

The Board hereby announces that Dr. Zeng Zhaowu (“**Dr. Zeng**”) has been re-designated from an independent non-executive Director to a non-executive Director with effect from 8 October 2026.

The biographical details of Dr. Zeng are set out below:

Dr. Zeng Zhaowu (曾昭武), aged 62, was an independent non-executive Director, the chairman of the audit committee (the “**Audit Committee**”) and remuneration committee (the “**Remuneration Committee**”) of the Board, and a member of the nomination committee (the “**Nomination Committee**”) of the Board from 15 June 2021 to 8 October 2026. Dr. Zeng was primarily responsible for overseeing and providing independent judgement to the Board. Dr. Zeng has over 30 years of experience in the finance and treasury industry. He graduated from Lingnan College of Sun Yat-sen University in the PRC with an undergraduate degree and a master’s degree, and obtained his PhD degree in finance and investment from the Business School of Sun Yat-sen University in 2003. Dr. Zeng was the deputy director of the Development Promotion Bureau of Guangdong Financial High-tech Service Zone* (廣東金融高新技術服務區發展促進局), a researcher at the Center for Financial and Industrial Development of Peking University, a researcher at the Financial Investment Research Center of Sun Yat-sen University, an MBA instructor at the Business School of Sun Yat-sen University, a visiting professor at the Foshan University and Guangdong University of Foreign Studies, and a member of the evaluation committee of the Guangzhou Returned Talents Entrepreneurship Project* (廣州歸國人才創業項目). He has solid theoretical background knowledge and extensive practical and management experience in the corporate management and financial markets such as securities, futures, foreign exchange, etc.

Dr. Zeng was a member of the National Futures Association (NFA), the business director of Guangdong International Trust and Investment Company* (廣東省國際信託投資公司), the vice president of Guangzhou Securities Company Limited, and the director of Foshan Finance Bureau* (佛山市金融局). He also served as the director of the office of the Foshan Postdoctoral Work Management Committee* (佛山市博士後工作管理委員會辦公室主任). He has written for the financial column in newspapers and magazines for years and published a number of books and articles, including a book on corporate financing titled Equity Refinancing of Listed Companies (《上市公司股權再融資》) (2004).

In respect of his re-designation, Dr. Zeng has entered into a new letter of appointment with the Company in relation to his appointment as a non-executive Director for an initial term of three years commencing from 8 October 2026 and shall continue thereafter unless terminated by not less than one month’s notice in writing served by either party. He is also subject to retirement and re-election at the next following annual general meeting of the Company after his appointment and thereafter subject to retirement by rotation and re-election at least once every three years according to the articles of association of the Company (the “**Articles**”), the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) and other applicable laws.

Dr. Zeng is entitled to receive a Director's fee of HK\$80,000 per annum. The remuneration payable to Dr. Zeng is recommended by the Remuneration Committee and approved by the Board with reference to his background, experience, time commitment and responsibilities, the remuneration policy of the Company as well as the prevailing market conditions, and shall be reviewed by the Remuneration Committee from time to time.

Save as disclosed herein, as at the date of this announcement, Dr. Zeng:

- (i) does not hold any position in the Company or other members of the Group;
- (ii) has not held any directorship in the last three years in other public companies the securities of which are listed on any securities market in Hong Kong or overseas;
- (iii) does not have any relationship with any Directors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and
- (iv) does not have any interest in the Shares or underlying Shares within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO").

Save as disclosed above and as far as the Directors are aware, there is no other information relating to his re-designation which is required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

Following Dr. Zeng's re-designation, the Board is also pleased to announce that Mr. Yu Ting ("Mr. Yu") has been appointed as an independent non-executive Director with effect from 8 October 2026.

The biographical details of Mr. Yu are set out below:

Mr. YU Ting (俞霆), aged 42, has over 20 years of experience in audit and financial consultancy. From September 2006 to May 2015, Mr. Yu served at Deloitte Touche Tohmatsu Certified Public Accountants LLP (Shanghai, China); and Deloitte & Touche LLP (Singapore) with his last position as the Manager, Audit Department. From June 2015 to December 2017, he was the Senior Manager, Audit Department of Ruihua Certified Public Accountants (Shanghai, China). From January 2018 to June 2023, Mr. Yu became the Partner, Audit and Advisory Department of SBA Stone Forest Corporate Advisory (Shanghai) Co., Ltd.. Since July 2023, he acts as the Partner of YSH Advisory Pte. Ltd. (Singapore).

In August 2006, Mr. Yu obtained his ACCA (the Association of Chartered Certified Accountants) professional certificate from Singapore Accountancy Academy. He is currently a fellow of the Association of Chartered Certified Accountants.

Mr. Yu has entered into a letter of appointment with the Company in relation to his appointment as an independent non-executive Director for an initial term of three years commencing from 8 October 2026 and shall continue thereafter unless terminated by not less than one month's notice in writing served by either party. He is also subject to retirement and re-election at the next following annual general meeting of the Company after his appointment and thereafter subject to retirement by rotation and re-election at least once every three years according to the Articles, the Listing Rules and other applicable laws.

Mr. Yu is entitled to receive a Director's fee of HK\$120,000 per annum. The remuneration payable to Mr. Yu is recommended by the Remuneration Committee and approved by the Board with reference to his background, experience, time commitment and responsibilities, the remuneration policy of the Company as well as the prevailing market conditions, and shall be reviewed by the Remuneration Committee from time to time.

Save as disclosed herein, as at the date of this announcement, Mr. Yu:

- (i) does not hold any position in the Company or other members of the Group;
- (ii) has not held any directorship in the last three years in other public companies the securities of which are listed on any securities market in Hong Kong or overseas;
- (iii) does not have any relationship with any Directors, senior management or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and
- (iv) does not have any interest in the Shares or underlying Shares within the meaning of Part XV of the SFO.

Mr. Yu has also confirmed that (i) he meets the independence criteria as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Company or its subsidiaries or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment.

Save as disclosed above and as far as the Directors are aware, there is no other information relating to his appointment which is required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders.

The Board would like to express its warmest welcome to Mr. Yu for joining the Board.

CHANGE IN COMPOSITION OF BOARD COMMITTEES

Following Dr. Zeng's re-designation, Dr. Zeng has ceased, and Mr. Yu has been appointed, to act as the chairman of each of the Audit Committee and Remuneration Committee and a member of the Nomination Committee.

By order of the Board
Xinji Shaxi Group Co., Ltd
Cheung Hon Chuen
Chairman

Guangzhou, the PRC, 8 October 2026

As at the date of this announcement, the Board comprises Mr. Cheung Hon Chuen as chairman and executive Director (Mr. Zhang Weiquan as his alternate); Mr. Mei Zuoting (Mr. Mei Jiawei as his alternate) and Mr. Zhang Weixin (Mr. Zhang Jiajian as his alternate) as executive Directors; Dr. Zeng Zhaowu, Mr. Lin Lie and Ms. Wang Yixue as non-executive Directors; and Mr. Tan Michael Zhen Shan, Dr. Zheng Decheng and Mr. Yu Ting as independent non-executive Directors.